-
公开(公告)号:PE20011232A1
公开(公告)日:2001-12-08
申请号:PE2001000299
申请日:2001-03-30
Applicant: ABBOTT LAB
Inventor: DICKMAN DANIEL A , CHEMBURKAR SANJAY , HENRY RODGER F , NIU YUPING , PORTER WILLIAM , LECHUGA-BALLESTEROS DAVID , FORT JAMES J
IPC: A61K20060101 , A61K31/513 , A61P20060101 , A61P31/18 , A61P43/00 , C07D20060101 , C07D239/00 , C07D239/10
Abstract: SE REFIERE A LA FORMA CRISTALINA HIDRATADA O SOLVATADA DE LOPINAVIR (2S,3S,5S)-2-(2,6-DIMETILFENOXIACETIL)AMIN-3-HIDROXI-5-(2-(1-TETRAHIDROPIRIMID-2-ONIL)-3-METILBUTANOL)AMIN-1,6-DIFENILHEXANO) DE FORMULA I CARACTERIZADA POR PRESENTAR UN ESPECTRO INFRARROJO; UN PATRON DE DIFRACCION DE RAYOS X. EL LOPINAVIR ES UN INHIBIDOR DE PROTEASA DEL VIH
-
公开(公告)号:CA2936497C
公开(公告)日:2018-04-17
申请号:CA2936497
申请日:2006-12-12
Applicant: ABBOTT LAB
Inventor: DHAON MADHUP , HSIAO CHI-NUNG , PATEL SUBHASH , BONK PETER , CHEMBURKAR SANJAY , CHEN YONG
IPC: C07D498/18 , A61K31/436
Abstract: A single-step, one-pot process to obtain zotarolimus and other rapamycin derivatives on large scale that improves currently available syntheses. In one embodiment, dried rapamycin is dissolved in isopropylacetate. After cooling and 2,6-Lutidine addition, triflic anhydride is slowly added at -30°C. Salts are removed by filtration. Tetrazole, followed by a tert-base diisopropylethylamine is added. After incubation at room temperature, the product is concentrated and purified by a silica gel column using THF/heptane as eluant. The product is collected, concentrated, and purified using a heptane/acetone column. The product-containing fractions are concentrated. The product is dissolved in .tau.-BME and precipitated with heptane. The solids are dissolved in acetone, treated with butylated-hydroxy toluene, and the solution concentrated. The process is repeated twice with acetone to remove solvents. At least one stabilizing agent is added, such as BHT at 0.5% before drying.
-
公开(公告)号:BRPI0619844A2
公开(公告)日:2011-10-18
申请号:BRPI0619844
申请日:2006-12-12
Applicant: ABBOTT LAB
Inventor: DHAON MADHUP , HSIAO CHU-NUNG , PATEL SUBHASH , BONK PETER , CHEMBURKAR SANJAY , CHEN YONG
IPC: C07D498/18 , A61K31/395
Abstract: A single-step, one-pot process to obtain zotarolimus and other rapamycin derivatives on large scale that improves currently available syntheses. In one embodiment, dried rapamycin is dissolved in isopropylacetate. After cooling and 2,6-Lutidine addition, triflic anhydride is slowly added at -30°C. Salts are removed by filtration. Tetrazole, followed by a tert-base diisopropylethylamine is added. After incubation at room temperature, the product is concentrated and purified by a silica gel column using THF/heptane as eluant. The product is collected, concentrated, and purified using an acetone/heptane column. The product-containing fractions are concentrated. The product is dissolved in t-BME and precipitated with heptane. The solids are dissolved in acetone, treated with butylated-hydroxy toluene, and the solution concentrated. The process is repeated twice with acetone to remove solvents. At least one stabilizing agent is added, such as BHT at 0.5% before drying.
-
公开(公告)号:NO327320B1
公开(公告)日:2009-06-08
申请号:NO20042393
申请日:2004-06-09
Applicant: ABBOTT LAB
Inventor: BAUER JOHN F , SALEKI-GERHARDT AZITA , NARAYANAN BIKSHANDARKOIL A , CHEMBURKAR SANJAY , PATEL KETAN
IPC: C07D277/28 , A61K31/426 , A61K31/427 , A61P31/18 , A61P37/04 , C07D277/24 , C07D277/30 , C07D277/36 , C07D277/40 , C07D277/42 , C07D417/12
Abstract: This Application concerns the use of Form II crystalline ritonavir as a pharmaceutical agent, as well as methods of preparing pharmaceutical compositions, which methods employ Form II crystalline ritonavir. The Application further concerns methods for obtaining Form I crystalline ritonavir, which methods employ Form II crystalline ritonavir.
-
公开(公告)号:AT418973T
公开(公告)日:2009-01-15
申请号:AT03774943
申请日:2003-10-22
Applicant: ABBOTT LAB
Inventor: BENNANI YOUSSEF , BUNNELLE WILLIAM , CHANG SOU-JEN , CHEMBURKAR SANJAY , CHEN JINHUA , DART MICHAEL , FERNANADO DILINIE , KU YI-YIN , LOCKWOOD MARK , WANG LEI
IPC: A61K31/16 , A61K31/19 , A61P25/00 , A61P29/00 , C07C61/00 , C07C61/13 , C07C61/135 , C07C69/753 , C07C229/00 , C07C233/00 , C07C233/58 , C07C233/60 , C07C233/63
-
公开(公告)号:NO325005B1
公开(公告)日:2008-01-14
申请号:NO20024679
申请日:2002-09-30
Applicant: ABBOTT LAB
Inventor: CHEMBURKAR SANJAY , LECHUGA-BALLESTEROS DAVID , DICKMAN DANIEL A , FORT JAMES J , HENRY RODGER F , NIU YUPING , PORTER WILLIAM
IPC: C07D239/10 , A61K20060101 , A61K31/513 , A61P20060101 , A61P31/18 , A61P43/00 , C07D20060101
Abstract: New crystalline forms of lopinavir are disclosed.
-
公开(公告)号:AT361913T
公开(公告)日:2007-06-15
申请号:AT01966367
申请日:2001-08-29
Applicant: ABBOTT LAB
Inventor: CHEMBURKAR SANJAY , PATEL KETAN , SPIWEK HARRY
IPC: C07D239/10 , C07B53/00 , C07D403/06 , C07D521/00
Abstract: The instant invention provides processes and intermediates employed in the synthesis of ((2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S-(1-tetrahydropyrimid-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane and analogs thereof.
-
公开(公告)号:NO20024679D0
公开(公告)日:2002-09-30
申请号:NO20024679
申请日:2002-09-30
Applicant: ABBOTT LAB
Inventor: DICKMAN DANIEL A , CHEMBURKAR SANJAY , FORT JAMES J , HENRY RODGER F , LECHUGA-BALLESTEROS DAVID , NIU YUPING , PORTER WILLIAM
IPC: A61K20060101 , A61K31/513 , A61P20060101 , A61P31/18 , A61P43/00 , C07D20060101 , C07D239/10 , C07D
Abstract: New crystalline forms of lopinavir are disclosed.
-
公开(公告)号:UY26643A1
公开(公告)日:2001-10-25
申请号:UY26643
申请日:2001-03-29
Applicant: ABBOTT LAB
Inventor: DICKMAN DANIEL A , CHEMBURKAR SANJAY , FORT JAMES J , HENRY RODGER F , LECHUGA-BALLESTEROS DAVID , NIU YUPING , PORTER WILLIAM
Abstract: Se describen nuevas formas cristalinas de lopinavir.
-
公开(公告)号:CA2403635A1
公开(公告)日:2001-10-11
申请号:CA2403635
申请日:2001-03-21
Applicant: ABBOTT LAB
Inventor: CHEMBURKAR SANJAY , DICKMAN DANIEL A , FORT JAMES J , NIU YUPING , HENRY RODGER F , LECHUGA-BALLESTEROS DAVID , PORTER WILLIAM
IPC: A61K20060101 , A61K31/513 , A61P20060101 , A61P31/18 , A61P43/00 , C07D20060101 , C07D239/10 , A61K31/505
Abstract: New crystalline forms of lopinavir are disclosed.
-
-
-
-
-
-
-
-
-